Status:
UNKNOWN
Aliskiren and Muscle Sympathetic Nerve Activity
Lead Sponsor:
UMC Utrecht
Conditions:
Chronic Kidney Disease
Hypertension
Eligibility:
All Genders
25-95 years
Phase:
PHASE4
Brief Summary
The central hypothesis of this project is that Aliskiren causes a substantial decrease in MSNA in hypertensive patients with CKD.
Detailed Description
Cardiovascular (CV) morbidity and mortality are frequently occurring problems in chronic kidney disease (CKD) patients. Apart from the so called traditional risk factors, also risk factors more or les...
Eligibility Criteria
Inclusion
- Patients with stable chronic kidney disease and hypertension: i.e. using antihypertensive drugs and/or blood pressure \> 145/90 mmHg when off medication.
- Patients on ACE inhibitor or ARB
Exclusion
- Patients with diabetes mellitus
- Patients on renal replacement therapy
- Pregnant patients Using of antihypertensive which cannot be stopped
- Patients on immunosuppressive therapy and active nephrotic syndrome
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00719316
Start Date
July 1 2008
End Date
January 1 2010
Last Update
January 14 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center utrecht
Utrecht, Utrecht, Netherlands, 3584CX